{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:30:02Z","timestamp":1793734202031,"version":"4.6.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>The introduction of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has transformed the management of severe retinopathy of prematurity (ROP) in the zone I\/zone II posterior region and aggressive ROP by enabling rapid disease regression while preserving peripheral retinal tissue and improving refractive outcomes compared with laser photocoagulation. Nevertheless, there is a risk of late disease recurrence, which has resulted in interest in longer-acting agents such as aflibercept. Aflibercept is a potent VEGF trap with high binding affinity and prolonged intraocular activity, with the possibility of reducing recurrence compared with other anti-VEGF agents. Early retrospective and prospective studies using 1 mg dose of intravitreal aflibercept have demonstrated high rates of initial regression and favorable refractive outcomes. Subsequently, the pivotal FIREFLEYE and BUTTERFLEYE randomized controlled trials evaluated low-dose aflibercept (0.4 mg) against laser, reporting comparable treatment success but higher recurrence with aflibercept, alongside advantages such as rapid disease regression, preservation of peripheral retina, and lower rates of high myopia. Reactivation following aflibercept generally occurs less frequently and later than with ranibizumab and at a similar or lower rate than bevacizumab; however, persistent avascular retina remains a significant concern, necessitating prolonged surveillance and, when indicated, adjunctive laser treatment. Available systemic safety data are very limited, including pharmacokinetic analyses, but suggest transient systemic exposure without evidence of short-term adverse effects on growth or neurodevelopmental outcomes. The following review focuses on the role of intravitreal aflibercept in ROP.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3323_25","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:18Z","timestamp":1777478478000},"page":"735-747","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Current role of aflibercept in retinopathy of prematurity \u2013 A review"],"prefix":"10.4103","volume":"74","author":[{"given":"Devesh","family":"Kumawat","sequence":"first","affiliation":[{"name":"Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawazish","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parijat","family":"Chandra","sequence":"additional","affiliation":[{"name":"Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/APO.0000000000000313","article-title":"Retinopathy of prematurity: How to prevent the third epidemics in developing countries","volume":"9","author":"Azad","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0002-9394(77)90377-4","article-title":"Retinal vascular development in premature infants","volume":"84","author":"Roth","year":"1977","journal-title":"Am J Ophthalmol"},{"key":"R4-20261103","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3928\/01913913-20210423-01","article-title":"An observational study of different treatment practices for aggressive posterior retinopathy of prematurity","volume":"58","author":"Kumari","year":"2021","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R6-20261103","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41433-021-01392-6","article-title":"Aggressive posterior retinopathy of prematurity: A review on current understanding","volume":"35","author":"Kumawat","year":"2021","journal-title":"Eye (Lond)"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: The FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/bjo-2025-327597","article-title":"Reactivation of retinopathy of prematurity after anti-VEGF treatment: A review","volume":"110","author":"Kumawat","year":"2026","journal-title":"Br J Ophthalmol"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"Wu","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: A VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5301\/ejo.5000938","article-title":"Effect of intravitreal aflibercept on central retinal arterial blood flow in type 1 retinopathy of prematurity","volume":"27","author":"Sukgen","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"884","DOI":"10.4103\/ijo.IJO_708_18","article-title":"Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity","volume":"67","author":"Vedantham","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s10792-018-1040-x","article-title":"Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography","volume":"39","author":"Vural","year":"2019","journal-title":"Int Ophthalmol"},{"key":"R21-20261103","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1097\/IAE.0000000000002754","article-title":"Anatomical and functional results of intravitreal aflibercept monotherapy for type 1 retinopathy of prematurity: One-year outcomes","volume":"40","author":"Chen","year":"2020","journal-title":"Retina"},{"key":"R22-20261103","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3928\/01913913-20191104-01","article-title":"Comparison of the efficacy between intravitreal aflibercept and laser photocoagulation in the treatment of retinopathy of prematurity","volume":"57","author":"Ekinci","year":"2020","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R23-20261103","doi-asserted-by":"crossref","first-page":"93.e1","DOI":"10.1016\/j.jaapos.2020.11.020","article-title":"Comparison of two different doses of intravitreal aflibercept in the treatment of retinopathy of prematurity","volume":"25","author":"Ekinci","year":"2021","journal-title":"J AAPOS"},{"key":"R24-20261103","doi-asserted-by":"crossref","first-page":"e248383","DOI":"10.1001\/jamanetworkopen.2024.8383","article-title":"Intravitreal aflibercept vs laser therapy for retinopathy of prematurity: Two-year efficacy and safety outcomes in the nonrandomized controlled trial FIREFLEYE next","volume":"7","author":"Stahl","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R25-20261103","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40942-021-00334-4","article-title":"Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity","volume":"7","author":"Riazi-esfahani","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000503568","article-title":"Comparison of vascular outgrowth rate and retinal vascular development border after intravitreal injection of aflibercept or bevacizumab to treat retinopathy of prematurity","volume":"243","author":"Vural","year":"2020","journal-title":"Ophthalmologica"},{"key":"R27-20261103","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R28-20261103","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/joco.joco_193_21","article-title":"Comparison of clinical outcomes of intravitreal bevacizumab and aflibercept in type 1 prethreshold retinopathy of prematurity in posterior zone II","volume":"34","author":"Eftekhari Milani","year":"2022","journal-title":"J Curr Ophthalmol"},{"key":"R29-20261103","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1097\/IAE.0000000000003590","article-title":"Long-term effects of anti-vegf monotherapy for retinopathy of prematurity on the retinal and refractive development of eye","volume":"42","author":"Sukgen","year":"2022","journal-title":"Retina"},{"key":"R30-20261103","first-page":"1207","article-title":"[Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity]","volume":"24","author":"Hao","year":"2022","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"R31-20261103","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"S\u00fcren","year":"2022","journal-title":"Int Ophthalmol"},{"key":"R32-20261103","doi-asserted-by":"crossref","first-page":"31097","DOI":"10.1038\/s41598-024-82445-0","article-title":"A comparation of three different anti-VEGF drugs in development of persistent avascular retina in premature children","volume":"14","author":"\u00dcnal","year":"2024","journal-title":"Sci Rep"},{"key":"R33-20261103","doi-asserted-by":"crossref","first-page":"113913","DOI":"10.1016\/j.jpeds.2024.113913","article-title":"Clinical risk factors for retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor injection","volume":"273","author":"Lee","year":"2024","journal-title":"J Pediatr"},{"key":"R34-20261103","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.clinthera.2024.08.011","article-title":"Efficacy and safety of aflibercept and ranibizumab in the treatment of retinopathy of prematurity","volume":"46","author":"Yang","year":"2024","journal-title":"Clin Ther"},{"key":"R35-20261103","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/ceo.14575","article-title":"Comparison of clinical and angiographic outcomes of ranibizumab and aflibercept in type 1 and aggressive retinopathy of prematurity","volume":"53","author":"Zhang","year":"2025","journal-title":"Clin Exp Ophthalmol"},{"key":"R36-20261103","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40001-024-02206-7","article-title":"Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity","volume":"30","author":"Huang","year":"2025","journal-title":"Eur J Med Res"},{"key":"R38-20261103","first-page":"5126","article-title":"Effect of intravitreal aflibercept versus laser photocoagulation for retinopathy of prematurity: Results from the phase 3 BUTTERFLEYE trial","volume":"64","author":"Moshfeghi","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R39-20261103","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3928\/23258160-20211124-01","article-title":"Aflibercept for retinopathy of prematurity: A systematic review and meta-analysis","volume":"52","author":"Chen","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R40-20261103","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"key":"R41-20261103","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3390\/jcm14030810","article-title":"A review of refractive errors post anti-vascular endothelial growth factor injection and laser photocoagulation treatment for retinopathy of prematurity","volume":"14","author":"Wang","year":"2025","journal-title":"J Clin Med"},{"key":"R42-20261103","first-page":"585","article-title":"Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis","volume":"69","author":"Ortiz-Seller","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"R43-20261103","first-page":"e73286","article-title":"Recurrence of retinopathy of prematurity following anti-vascular endothelial growth factor (Anti-VEGF) therapy: A systematic review and meta-analysis","volume":"16","author":"Dablouk","year":"2024","journal-title":"Cureus"},{"key":"R44-20261103","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/aos.12604","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: A randomised, prospective trial","volume":"93","author":"Zehetner","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"R45-20261103","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10384-021-00895-9","article-title":"Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity","volume":"66","author":"Furuncuoglu","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"R46-20261103","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","article-title":"Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity","volume":"256","author":"Huang","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R47-20261103","doi-asserted-by":"crossref","first-page":"e000185","DOI":"10.1136\/bmjophth-2018-000185","article-title":"Systemic pharmacokinetic\/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases","volume":"4","author":"Kaiser","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"R48-20261103","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/s41433-023-02919-9","article-title":"Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: Results from the FIREFLEYE randomized phase 3 study","volume":"38","author":"Stahl","year":"2024","journal-title":"Eye (Lond)"},{"key":"R50-20261103","first-page":"2621","article-title":"Efficacy and safety outcomes from the FIREFLEYE next study of children 3 years of age treated with intravitreal aflibercept or laser for retinopathy of prematurity (ROP) in the randomized FIREFLEYE study","volume":"66","author":"Stahl","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3323_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:19Z","timestamp":1793732419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3323_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3323_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-12-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}